FibroGen (FGEN) Highlights Latest Data from PRAISE Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis
Tweet Send to a Friend
FibroGen, Inc. (NASDAQ: FGEN) today announced that updated results from the company’s randomized, double-blind, placebo-controlled Phase 2b PRAISE study of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
